These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 24864079)

  • 41. Potential of anti-inflammatory agents for treatment of atherosclerosis.
    Chistiakov DA; Melnichenko AA; Grechko AV; Myasoedova VA; Orekhov AN
    Exp Mol Pathol; 2018 Apr; 104(2):114-124. PubMed ID: 29378168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hegemony of inflammation in atherosclerosis and coronary artery disease.
    Attiq A; Afzal S; Ahmad W; Kandeel M
    Eur J Pharmacol; 2024 Mar; 966():176338. PubMed ID: 38242225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microbe-Derived Antioxidants Reduce Lipopolysaccharide-Induced Inflammatory Responses by Activating the Nrf2 Pathway to Inhibit the ROS/NLRP3/IL-1β Signaling Pathway.
    Shen C; Luo Z; Ma S; Yu C; Gao Q; Zhang M; Zhang H; Zhang J; Xu W; Yao J; Xu J
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
    Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M
    Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways.
    Carlson NG; Wieggel WA; Chen J; Bacchi A; Rogers SW; Gahring LC
    J Immunol; 1999 Oct; 163(7):3963-8. PubMed ID: 10490998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P2X
    Peikert A; König S; Suchanek D; Rofa K; Schäfer I; Dimanski D; Karnbrock L; Bulatova K; Engelmann J; Hoppe N; Wadle C; Heidt T; Albrecht P; von Garlen S; Härdtner C; Hilgendorf I; Wolf D; von Zur Mühlen C; Bode C; Zirlik A; Duerschmied D; Merz J; Stachon P
    Sci Rep; 2022 Feb; 12(1):2801. PubMed ID: 35181718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
    Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
    Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging Anti-Atherosclerotic Therapies.
    Gluba-Brzózka A; Franczyk B; Rysz-Górzyńska M; Ławiński J; Rysz J
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
    Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
    Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new strategy for the treatment of atherothrombosis - inhibition of inflammation.
    Slíva J; Charalambous C; Bultas J; Karetová D
    Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
    Front Immunol; 2020; 11():971. PubMed ID: 32670263
    [No Abstract]   [Full Text] [Related]  

  • 53. Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-κB innate response pathways.
    Rahman MM; McFadden G
    J Virol; 2011 Dec; 85(23):12505-17. PubMed ID: 21957307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs.
    Li Y; Xu S; Jiang B; Cohen RA; Zang M
    PLoS One; 2013; 8(6):e67532. PubMed ID: 23825667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence.
    Mangoni AA; Zinellu A; Sotgia S; Carru C; Piga M; Erre GL
    Mediators Inflamm; 2017; 2017():9632846. PubMed ID: 29430085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the unstable plaque in acute coronary syndromes.
    Thompson PL; Nidorf SM; Eikelboom J
    Clin Ther; 2013 Aug; 35(8):1099-107. PubMed ID: 23973042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
    Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
    Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet.
    Abderrazak A; Couchie D; Mahmood DF; Elhage R; Vindis C; Laffargue M; Matéo V; Büchele B; Ayala MR; El Gaafary M; Syrovets T; Slimane MN; Friguet B; Fulop T; Simmet T; El Hadri K; Rouis M
    Circulation; 2015 Mar; 131(12):1061-70. PubMed ID: 25613820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ZeXieYin formula alleviates atherosclerosis by inhibiting the MAPK/NF-κB signaling pathway in APOE-/- mice to attenuate vascular inflammation and increase plaque stability.
    Huang R; Sun Y; Liu R; Zhu B; Zhang H; Wu H
    J Ethnopharmacol; 2024 Jun; 327():117969. PubMed ID: 38437888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.